Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux.

NCT00555438 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

451

Enrollment

OTHER

Sponsor class

Conditions

Major Orthopaedic Surgery and Renal Impairment

Interventions

DRUG: fondaparinux 1.5 mg/day

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Collaborators

[object Object]